Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection

Abstract

Summary The COVID-19 pandemic is an unprecedented global challenge. Highly variable in its presentation, spread and clinical outcome, novel point-of-care diagnostic classifiers are urgently required. Here, we describe a set of COVID-19 clinical classifiers discovered using a newly designed low-cost high-throughput mass spectrometry-based platform. Introducing a new sample preparation pipeline coupled with short-gradient high-flow liquid chromatography and mass spectrometry, our methodology facilitates clinical implementation and increases sample throughput and quantification precision. Providing a rapid assessment of serum or plasma samples at scale, we report 27 biomarkers that distinguish mild and severe forms of COVID-19, of which some may have potential as therapeutic targets. These proteins highlight the role of complement factors, the coagulation system, inflammation modulators as well as pro-inflammatory signalling upstream and downstream of Interleukin 6. Application of novel methodologies hence transforms proteomics from a research tool into a rapid-response, clinically actionable technology adaptable to infectious outbreaks. Highlights - A completely redesigned clinical proteomics platform increases throughput and precision while reducing costs. - 27 biomarkers are differentially expressed between WHO severity grades for COVID-19. - The study highlights potential therapeutic targets that include complement factors, the coagulation system, inflammation modulators as well as pro-inflammatory signalling both upstream and downstream of interleukin 6.

Cited by papers we hold 14

• Elevated IFNA1 and suppressed IL12p40 associated with persistent hyperinflammation in COVID-19 pneumonia · 2023
  Not checked
• Multi-Omics Profiling for Health · 2023
  No notice
• MS-Based Proteomics of Body Fluids: The End of the Beginning · 2023
  No notice
• SARS‐CoV‐2 targeting by RNAi and host complement inhibition: A two‐pronged subterfuge for COVID‐19 treatment · 2022
  Not checked
• dia-PASEF data analysis using FragPipe and DIA-NN for deep proteomics of low sample amounts · 2022
  No notice
• Ultra‐high sensitivity mass spectrometry quantifies single‐cell proteome changes upon perturbation · 2022
  No notice
• LRG1: an emerging player in disease pathogenesis · 2022
  No notice
• Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection · 2021
  No notice
• Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in the general population · 2021
  No notice
• High‐resolution serum proteome trajectories in COVID‐19 reveal patient‐specific seroconversion · 2021
  No notice
• SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care · 2021
  No notice
• Circulating Exosomes Are Strongly Involved in SARS-CoV-2 Infection · 2021
  No notice
• Genetic architecture of host proteins involved in SARS-CoV-2 infection · 2020
  Corrected
• A high-stringency blueprint of the human proteome · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.